Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Healthtrust
McKesson
Dow
Deloitte
Cipla
Argus Health
Chubb

Generated: May 20, 2018

DrugPatentWatch Database Preview

IMPAVIDO Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Impavido, and what generic alternatives are available?

Impavido is a drug marketed by Knight Theraps and is included in one NDA.

The generic ingredient in IMPAVIDO is miltefosine. Two suppliers are listed for this compound. Additional details are available on the miltefosine profile page.
Drug patent expirations by year for IMPAVIDO
Pharmacology for IMPAVIDO
Drug ClassAntileishmanial
Synonyms for IMPAVIDO
[2-(Hexadecyloxy-hydroxy-phosphoryloxy)-ethyl]-trimethyl-ammonium
1-Hexadecylphosphorylcholine
1-N-HEXADECYLPHOSPHORYLCHOLINE
2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide
2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt
2-[[(Hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium
2-[hexadecoxy(hydroxy)phosphoryl]oxyethyl-trimethyl-ammonium
3, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
4-04-00-01460 (Beilstein Handbook Reference)
53EY29W7EC
58066-85-6
93597-88-7
A831718
AB00642217_04
AB00642217-03
AC1L1GAH
AK163678
AKOS015914886
AN-8651
Baxter brand of miltefosine
Baxter Oncology brand of miltefosine
BCP0726000071
BCP9000927
BDBM50034220
BG0492
BRN 3690495
C15H32.C7H17NO4P
C21H46NO4P
CAS-58066-85-6
CCG-35584
CCG-36097
CCG-40025
CHEBI:75283
CHEMBL125
Choline hexadecyl phosphate
Choline hydroxide, hexadecyl hydrogen phosphate, inner salt
Choline phosphate, hexadecyl ester, hydroxide, inner salt
Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI)
Choline, hexadecyl hydrogen phosphate, inner salt
Choline, inner salt
CS-2933
CTK8G1121
D 18506
D-18506
D00FGR
D02494
D18506
DB09031
DL-131
DR002417
DSSTox_CID_25942
DSSTox_GSID_45942
DSSTox_RID_81240
DTXSID7045942
ETH098
Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt
Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt
Ethanaminium, 2-[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt
Fos-choline 16
FT-0608148
H-1850
HDPC
HePC
HePC Hydrate
hexadecyl (2-(trimethylAmmonio)ethyl) phosphate
Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate
hexadecyl 2-(trimethyl-lambda~5~-azanyl)ethyl hydrogen phosphate
hexadecyl 2-(trimethylammonio)ethyl phosphate
Hexadecyl 2-(Trimethylammonio)ethyl Phosphate Hydrate
hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
hexadecyl phosphocholine
Hexadecyl Phosphorylcholine
Hexadecyl Phosphorylcholine Hydrate
hexadecyloxy-2-trimethylammonioethylphosphorate
Hexadecylphosphocholine
hexadecylphosphocholine, miltefosine
Hexadecylphosphorylcholine
HMS1922D16
HMS2089J15
HMS3649I09
HY-13685
I14-7244
Impavido (TN)
Impavidotrade mark
IN1227
KS-00000L54
LP041112
LS-65132
M-7200
M2445
MFCD00133396
Miltefos
miltefosin
Miltefosin C
Miltefosina
Miltefosina [INN-Spanish]
Miltefosine
miltefosine (hexadecylphosphocholine)
Miltefosine (INN)
Miltefosine [INN:BAN]
Miltefosine and HePC
Miltefosine, >=98% (perchloric acid titration)
Miltefosine[INN:BAN]
Miltefosinum
Miltefosinum [INN-Latin]
Miltex
Miltextrade mark
MMV688990
MolPort-003-665-519
monohexadecylphosphocholine
monohexadecylphosphorylcholine
n-hexadecylphosphocholine
n-Hexadecylphosphorylcholine
NCGC00095169-01
NCGC00095169-02
NCGC00095169-03
NCGC00095169-05
NSC 605583
NSC-605583
NSC-758968
NSC605583
NSC758968
Pharmakon1600-01505329
Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester
Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester Hydrate
PQLXHQMOHUQAKB-UHFFFAOYSA-N
Prasfarma brand of miltefosine
s3056
SCHEMBL26215
SPECTRUM1505329
ST51055612
TF-002
Tox21_111466
Tox21_111466_1
UNII-53EY29W7EC

US Patents and Regulatory Information for IMPAVIDO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Knight Theraps IMPAVIDO miltefosine CAPSULE;ORAL 204684-001 Mar 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Knight Theraps IMPAVIDO miltefosine CAPSULE;ORAL 204684-001 Mar 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
Express Scripts
UBS
Accenture
Healthtrust
Julphar
QuintilesIMS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.